A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Novartis
Novartis
BioNTech SE
Hoffmann-La Roche
Amgen
Debiopharm International SA
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Astellas Pharma Inc
FBD Biologics Limited
AstraZeneca
Beijing Pearl Biotechnology Limited Liability Company
Boehringer Ingelheim
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Servier
Biotheus Inc.
AstraZeneca
EpicentRx, Inc.